Home Icon

Loading, Please Wait...

Aptevo Therapeutics Introduces New Adaptir™ Bispecific Antibody Candidate Intended for the Treatment of Solid Tumors

1013 Days ago

New ADAPTIR Candidate APVO603 is a Dual-Agonistic Bispecific
Antibody Targeting 4-1BB and OX40

APVO603 is Designed to Induce Synergistic Effects on Immune Responses
with Potential to Enhance Anti-Tumor Immune Response Against Solid Tumors

SEATTLE, Sept. 19, 2019 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq: APVO), a biotechnology company focused on developing novel oncology, autoimmune and hematology therapeutics, today introduced a new immuno-oncology candidate, APVO603, built on Aptevo’s proprietary ADAPTIR™ bispecific antibody platform.  Dr. Jane Gross, Chief Scientific Officer for Aptevo, will present preclinical data on APVO603 in an oral presentation today at the 10th Annual World Bispecific Summit in Waltham, MA.

APVO603 is a dual agonist bispecific antibody employing a novel mechanism of action to simultaneously target 4-1BB (CD137) and OX40 (CD134), both members of the TNF-receptor family.  Dual targeting of 4-1BB and OX40 provides synergistic co-stimulation of T cells with the potential to amplify the cytotoxic function of activated T cells and NK cells, potentially leading to more robust anti-tumor responses. 

“Aptevo continues to create new, innovative molecules based on our ADAPTIR platform technology and we are excited to introduce our newest bispecific antibody candidate, APVO603,” said Jane Gross, Ph.D., Chief Scientific Officer for Aptevo. “APVO603 demonstrates the versatility and flexibility of our ADAPTIR platform to generate multiple candidates with diverse mechanisms of action (T-cell engagers, T-cell co-stimulators and targeted cytokines) for the treatment of cancer and autoimmune diseases.  Importantly, this flexibility allows us to engineer novel molecules addressing both hematological cancers and solid tumors – a significant area of unmet medical need within the field of immuno-oncology therapeutics.”

“We believe that a targeted strategy combining activation of both the 4-1BB and OX40 TNF receptors represents an attractive approach in potentially overcoming the suppressive tumor microenvironment,” continued Dr. Gross.  “The targeted co-stimulation of 4-1BB and OX40 has the potential to promote an important immunological cascade, enhancing T-cell activation, prolonging T-cell survival, and improving tumor killing.  We look forward to furthering our preclinical work and advancing APVO603 towards clinical development.”
The potential advantages of APVO603 include:

  • Broad Utility:  Unlike chimeric antigen receptor T-cell therapies (CAR-T) and bispecific CD3-based T-cell engagers, APVO603 does not target a specific tumor antigen, thus allowing for broad potential therapeutic use for a number of different types of solid tumors. 
  • Reduced Toxicity:  Since 4-1BB and OX40 are costimulatory receptors that are primarily expressed only on a limited number of T cells that have previously been exposed to tumor antigen, we believe APVO603 has the potential to cause less toxicity compared to traditional CD3-based T-cell engagers due to its selectivity.  
  • Differentiation from 4-1BB Agonistic Monoclonal Antibodies:  Because APVO603 contains an Fc that does not interact with Fc gamma receptors, it has the potential to be less toxic than monospecific 4-1BB antibodies.
  • Synergistic Activity: While the activation of either 4-1BB or OX40 alone stimulates anti-tumor T-cell responses, as a dual agonist bispecific antibody APVO603 has the potential to produce a synergistic or amplified response resulting in more robust T-cell responses.

“Bispecific antibodies are expected to be the cornerstone of the next generation of immuno-oncology products,” Dr. Gross continued.  “The key to success is having a technology and the necessary expertise to generate bispecifics with the desired activity, while maintaining excellent stability, half-life and manufacturing characteristics. Our demonstrated ability to create new molecules with novel function substantiates the power and versatility of the ADAPTIR platform.”

10th Annual World Bispecific Summit – Oral Presentation Details

Title: Utility of the ADAPTIR™ Platform to Engage and Modulate Immune Cells for Treatment of Cancer and Autoimmune and Inflammatory Diseases
Time: Thursday, September 19th, 2019, 12:00 pm E.T.
Session: Translational & Clinical Track:  Enhancing Efficacy While Maintaining Safety Throughout Preclinical and Clinical Development

The data to be presented will highlight the anti-tumor activity of APVO603 showing how it outperforms a monospecific 4-1BB antibody in multiple T-cell activation assays and promotes CD4, CD8 T-cell and NK cell activation and proliferation.  Furthermore, Dr. Gross will present preclinical in vitro study results describing how activation of 4-1BB (CD137) and OX40 (CD134) promotes synergistic co-stimulation of T cells with the potential to augment the cytotoxic function of activated T cells and NK cells.

About APVO603 and the ADAPTIR Platform

APVO603 is an optimized, next generation bispecific antibody candidate designed to simultaneously target 4-1BB and OX40 to bolster activation of CD4 and CD8 T cells and Natural Killer cells to enhance anti-tumor immune responses to tumors.  APVO603 was built on Aptevo’s proprietary ADAPTIR protein therapeutic platform. 

Focused on generating novel, targeted bispecific antibody-based immunotherapies for cancer and autoimmune diseases, the ADAPTIR platform offers key advantages over other bispecific formats, derived in part from the flexible and modular nature of the ADAPTIR structure. These advantages include: the potential to achieve potent biological activity; desirable manufacturability characteristics, and promote an extended half-life.  In preclinical studies, ADAPTIR CD3-based T-cell engagers achieve potent T-cell tumor cytotoxicity with reduced T-cell cytokine release compared to other bispecific platforms. The flexible ADAPTIR platform allows Aptevo to build candidates with diverse mechanisms of action, including Redirected T-Cell Cytotoxicity (RTCC); T-cell co-stimulation, and targeted cytokine release. Two ADAPTIR molecules (APVO436 targeting CD123 and CD3 for treatment of AML and other hematologic diseases, and APVO210, a targeted cytokine therapeutic for treatment of multiple autoimmune diseases) are currently in clinical development.  A third candidate, ALG.APV-527, (targeting 4-1BB and 5T4, a solid tumor antigen) and APVO603 (4-1BB and OX40) are in preclinical development.

About Aptevo Therapeutics Inc.

Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel oncology, autoimmune and hematology therapeutics to meaningfully improve patients’ lives.  Aptevo has a commercial product, IXINITY® coagulation factor IX (recombinant), approved and marketed in the United States for the treatment of Hemophilia B, and a versatile core technology – the ADAPTIR™ modular protein technology platform capable of generating highly-differentiated bispecific antibodies with unique mechanisms of action to treat cancer and autoimmune diseases.  Aptevo has a broad pipeline of novel investigational-stage bispecific antibody candidates focused in immuno-oncology and autoimmune disease and inflammation. For more information, please visit www.aptevotherapeutics.com

Safe Harbor Statement

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact, including, without limitation, statements regarding potential milestone payments, Aptevo’s outlook, financial performance or financial condition, Aptevo’s technology and related pipeline, collaboration and partnership opportunities, commercial portfolio, milestones, and any other statements containing the words “believes,” “expects,” “anticipates,” “intends,” “plans,” “forecasts,” “estimates,” “will” and similar expressions are forward-looking statements. These forward-looking statements are based on Aptevo’s current intentions, beliefs and expectations regarding future events. Aptevo cannot guarantee that any forward-looking statement will be accurate. Investors should realize that if underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could differ materially from Aptevo’s expectations. Investors are, therefore, cautioned not to place undue reliance on any forward-looking statement. Any forward-looking statement speaks only as of the date of this press release, and, except as required by law, Aptevo does not undertake to update any forward-looking statement to reflect new information, events or circumstances.

There are a number of important factors that could cause Aptevo’s actual results to differ materially from those indicated by such forward-looking statements, including a deterioration in Aptevo’s business or prospects; adverse developments in research and development; adverse developments in the U.S. or global capital markets, credit markets or economies generally; and changes in regulatory, social and political conditions. Additional risks and factors that may affect results are set forth in Aptevo’s filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K, as filed on March 18, 2019 and its subsequent reports on Form 10-Q and current reports on Form 8-K. The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from Aptevo’s expectations in any forward-looking statement.

Aptevo Therapeutics
Stacey Jurchison
Senior Director, Investor Relations and Corporate Communications

We Are Diffrent
Is your business listed correctly on America’s largest city directory network of 1,000 portals? Find your City Portal